Brief: Sprint Bioscience signs licence agreement for PIP4K2-program

Sprint Bioscience AB

07/07/2016 07:31

July 7 (Reuters) - Sprint Bioscience AB  SPRINT.ST : 
    * Signs licence agreement for PIP4K2-program with Petra 
Pharma Corporation 
    * Says can receive up to about $240 million in milestone 
payment including an upfront payment of $3 million 
 
Source text for Eikon:  ID:nWkrga0188  
     
Further company coverage:  SPRINT.ST  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))